inter-batch variability? [Regulatives / Guidelines]

posted by Dr_Dan  – 2010-08-04 10:29 (4097 d 22:58 ago) – Posting: # 5713
Views: 15,574

Dear all
I need your help regarding following problem: we performed 2 BA (pilot) and 2 BE (pivotal, one 2 way cross-over and one replicate design) studies with the same test formulation.
The batches we used were:
Study 1 (pilot): test 1 (lab scale), ref. 1, study centre 1
Study 2 (pilot): test 2, ref. 2, study centre 1
Study 3 (pivotal): test 2, ref. 1, study centre 2
Study 4 (pivotal): test 3, ref. 3, study centre 3
Both pivotal studies show bioequivalence, the pilot studies were not powered adequately to demonstrate bioequivalence but the results hint in this direction. The drug is highly variable.
The point estimator (AUC/Cmax) differ between the studies:
Study 1: 111/116
Study 2: 84/95
Study 3: 111/114
Study 4: 98/97
The assessor concludes that these different point estimators hint at inter batch variability of the test product (why not the reference?) and therefore a marketing authorisation can not be granted.
What should be our response, which argumentation could help to safe our product?
Your input is very much appreciated.
Kind regards

Kind regards and have a nice day

Complete thread:

 Admin contact
21,753 posts in 4,548 threads, 1,544 registered users;
online 11 (0 registered, 11 guests [including 5 identified bots]).
Forum time: Saturday 09:27 CEST (Europe/Vienna)

Medical researches can be divided into two sorts:
those who think that meta is better and those
who believe that pooling is fooling.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz